Market Size of Veterinary Infectious Disease Therapeutics Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 5.80 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Veterinary Infectious Disease Therapeutics Market Analysis
Microorganisms are tiny living creatures that are present everywhere, such as bacteria and viruses. Few of the thousands of species of microorganisms invade, multiply, and cause illness in animals and people. Most of the microorganisms live on the skin, in the mouth, upper airways and intestines without causing any harmful disease but some of the microorganism lives in or on a pet, or invades and causes disease depends on the nature of the microorganism and the state of the pet's natural defenses.
According to World Small Animal Veterinary Association (WSAVA), estimates that 60% to 80% of emerging diseases are zoonotic which indicates the importance of veterinarians in the identification, prevention, and control of infectious diseases. For Example, Rift Valley Fever is an endemic zoonotic disease in Africa and the Middle East that costs producers USD 427 million every year. Increasing prevalence of infectious disease and increasing demand for dairy, meat, and poultry products due to the increasing population size are the key driving factors in the veterinary infectious disease therapeutics market.
Veterinary Infectious Disease Therapeutics Industry Segmentation
As per the scope of the report, veterinary infectious diseases are the diseases that can get transmitted from one animal to another animal or into a human being. Despite their overwhelming abundance, relatively few of the hundreds of thousands of species of microorganisms invade, multiply, and cause illness in animals and people.
| By Product Type | |
| Antibiotics | |
| Antiviral | |
| Antifungal | |
| Amebicides | |
| Others |
| By Animal Type | |
| Dogs and Cats | |
| Horses | |
| Swine | |
| Poultry | |
| Other Animals |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Veterinary Infectious Disease Therapeutics Market Size Summary
The veterinary infectious disease therapeutics market is driven by the increasing prevalence of zoonotic diseases and the rising demand for animal products such as dairy, meat, and poultry. Microorganisms, including bacteria and viruses, play a significant role in causing illnesses in animals, with a notable percentage of emerging diseases being zoonotic. This highlights the critical role of veterinarians in identifying, preventing, and controlling these diseases. The market is further propelled by the growing pet ownership and advancements in research and development within veterinary therapeutics. Antibiotics remain a primary treatment option for bacterial infections in animals, with various classes available to address these challenges.
North America is anticipated to hold a significant share of the global market, driven by the increasing prevalence of veterinary infectious diseases and higher healthcare expenditure for companion animals in the region. The adoption of advanced veterinary products and technologies is also contributing to market growth. The competitive landscape of the veterinary infectious disease therapeutics market is characterized by the presence of several major players, including Elanco, Merck & Co. Inc, Boehringer Ingelheim Vetmedica, and Zoetis, among others. These companies are key contributors to the market's development, leveraging their expertise to address the evolving needs of animal health.
Veterinary Infectious Disease Therapeutics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Prevalence of Infectious Diseases in Animals
-
1.2.2 Technological Advancements in Development of New Drugs
-
-
1.3 Market Restraints
-
1.3.1 Stringent Government Regulations
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Product Type
-
2.1.1 Antibiotics
-
2.1.2 Antiviral
-
2.1.3 Antifungal
-
2.1.4 Amebicides
-
2.1.5 Others
-
-
2.2 By Animal Type
-
2.2.1 Dogs and Cats
-
2.2.2 Horses
-
2.2.3 Swine
-
2.2.4 Poultry
-
2.2.5 Other Animals
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle-East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle-East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Veterinary Infectious Disease Therapeutics Market Size FAQs
What is the current Veterinary Infectious Disease Therapeutics Market size?
The Veterinary Infectious Disease Therapeutics Market is projected to register a CAGR of 5.80% during the forecast period (2024-2029)
Who are the key players in Veterinary Infectious Disease Therapeutics Market?
Elanco, Merck & Co. Inc, Boehringer Ingelheim Vetmedica, Zoetis and Dechra Pharmaceuticals PLC are the major companies operating in the Veterinary Infectious Disease Therapeutics Market.
